Sucampo Pharmaceuticals, Inc. 4
4 · Sucampo Pharmaceuticals, Inc. · Filed Mar 16, 2015
Insider Transaction Report
Form 4
Lichtlen Peter
Chief Medical Officer
Transactions
- Award
Employee Stock Option (right to buy)
2015-03-04+44,000→ 225,400 totalExercise: $14.82Exp: 2025-03-04→ Class A Common Stock (44,000 underlying)
Footnotes (1)
- [F1]The option vests in 4 equal annual installments beginning on March 4, 2016